Taking aim at islet hormones with GLP-1: Is insulin or glucagon the better target?

Diabetes

Volumn 59, Issue 7, 2010, Pages 1572-1574

  D'Alessio, David A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS ISLET; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN;

EID: 77954292894     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0299     Document Type: Note

References (15)

1. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;1:14-16
2. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-4059
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157
4. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
5. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004;286:E882-E890
6. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE. Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008;93:103-109
7. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006;38:838-844 (Pubitemid 46051506)
8. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-429 (Pubitemid 34764798)
9. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744 (Pubitemid 23218642)
10. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-586
11. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-876 (Pubitemid 40115912)
12. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010;59:1765-1770
13. Mittelman SD, Fu YY, Rebrin K, Steil G, Bergman RN. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. J Clin Invest 1997;100:3121-3130 (Pubitemid 28022850)
14. Lewis GF, Vranic M, Giacca A. Glucagon enhances the direct suppressive effect of insulin on hepatic glucose production in humans. Am J Physiol 1997;272:E371-E378
15. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 1998;47:523-529